Development of Green Mei Products for the Prevention of Metabolic Syndrome

Chung Shan Medical University

Status: Completed

Conditions: Hypertension

Treatments: Dietary Supplement: MGF-4; Dietary Supplement: MGF-7

Study type: Interventional

Funder types: Other

Identifiers

NCT05039437

CS2-19033

Details and patient eligibility

About

The aim of this study is to investigate the antihypertensive effects of Mei-Gin formula-4 (MGF-4) and Mei-Gin formula-7.

Full description

It's a randomized, and single-blind trial and was designed to evaluate the effects of MGFs (MGF-4 and MGF-4) on blood pressure. 50 participants with hypertension (systolic blood pressure between 130-179 mmHg or diastolic blood pressure between 85-109 mmHg) who did not accept any hypertension medication were randomized allocated to either MGF-4 or MGF-7 group. Participants were instructed to take 4 capsules of MGF-4 or MGF-7 daily throughout the duration of the 8 weeks intervention study. After treatment, the change of the blood pressure and relative mechanism were analyzed.

Enrollment: 50 patients

Sex: All

Ages: 20 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• The age of the subject is 20 to 70 years old.
• The subject is a patient with hypertension (SBP is between 130-179 mmHg, DBP is between 85-109mmHg, one of the two can be diagnosed), and there are no serious illnesses requiring hospitalization during the study period treatment.
• No hypertension medication.
• The subject can understand the test process described in the consent form and the possible potential risks and benefits, and able to sign the consent form.
• The subjects shall observe diet control during the trial period.

Exclusion criteria

• Subjects diagnosed with cancer and still under active treatment.
• Subjects diagnosed with heart disease and still under active treatment.
• Other drugs are used, whose pharmacological effects may affect blood pressure or may aggravate the effects of drugs.
• Subjects who have systemic infection and need systemic antibiotics.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

50 participants in 2 patient groups

MGF-4

Experimental group

Description:

Take two MGF-4 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-4 and other excipients.

Treatment:

Dietary Supplement: MGF-4

MGF-7

Experimental group

Description:

Take two MGF-7 capsules twice a day for 8 weeks. A 250 mg capsule contents 243 mg MGF-7 and other excipients.

Treatment:

Dietary Supplement: MGF-7